Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Time interval for bridge to surgery placement has little short-term effects

29 Jun 2020

The time interval for the placement of a bridge to surgery (BTS) does not seem to affect the perioperative short-term outcomes in patients with obstructive colon cancer, a recent study has found.

Researchers retrospectively assessed 174 patients who underwent BTS placement. Of these, 75 underwent the procedure within 7 days (group 1), 56 within 8–14 days (group 2), and 43 after 14 days (group 3). The primary endpoint was a comparison of oncologic outcomes, including overall survival (OS), disease-free survival (DFS), and recurrence rate (RR).

The postoperative mortality rates for groups 1, 2, and 3 were 17.3 percent, 10.8 percent, and 9.3 percent. Despite an apparent trend, no statistical significance was detected (p=0.337). There were likewise no immediate postoperative deaths reported. Patients were followed for a mean of 46.2 months.

Severe complications, number of lymph nodes harvested, resection margins, pathologic findings, and the rate of adjuvant chemotherapy after BTS were likewise comparable across groups.

In contrast to the short-term outcomes, multivariate analysis found that the time interval for BTS had significant effects in the long-run. Time interval appeared to be a significant predictor of DFS (hazard ratio [HR], 14.463, 95 percent confidence interval [CI], 1.458–3.255; p<0.001) and OS (HR, 4.917, 95 percent CI, 1.071–3.059; p<0.027). RR was also significantly different across groups (p=0.029).

“[T]he short-term perioperative outcomes in BTS after self-expandable metal stent (SEMS) placement were not affected by the time interval,” said researchers. “However, the long-term oncologic outcomes in patients who underwent elective surgery within 7 days after SEMS placement were better than in other patients.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.